Global Blood Therapeutics
-
Pfizer to buy sickle cell disease biotech Global Blood Therapeutics in $5.4B deal
Pfizer’s own R&D efforts in sickle cell disease have fallen short, so the pharmaceutical giant is turning to M&A to gain a presence in the blood disorder. The acquisition of Global Blood therapeutics brings the commercialized drug Oxbryta plus a pipeline of other therapeutic candidates.
-
Global Blood Therapeutics inks deal for two sickle cell disease drugs from Sanofi
In acquiring the two early-stage Sanofi drugs for sickle cell disease, Global Blood Therapeutics aims to complement Oxbryta, its FDA-approved treatment for the rare blood disorder. Meanwhile, Sanofi can turn its full sickle cell efforts on a gene-editing therapy partnered with Sangamo Therapeutics.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Let data – not politics – guide development of Covid-19 drugs, vaccines, biotech execs urge
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
-
Analysts weigh in on what to expect in biopharma this year
The first FDA approval for a NASH drug, data on “off-the-shelf” CAR-T cells and a potential approval of a controversial drug for Alzheimer’s disease are some of things in store for 2020.
-
FDA approves Global Blood Therapeutics’ drug targeting root cause of sickle cell disease
The agency gave accelerated approval to GBT’s Oxbryta (voxelotor) for sickle cell disease in patients aged 12 and older. The drug works by inhibiting sickle hemoglobin polymerization.
-
FDA accepts application for Global Blood’s sickle cell disease drug
The agency granted the application for accelerated approval priority review, but is not requiring an advisory committee meeting. A confirmatory trial measuring the drug’s ability to reduce stroke risk is planned for the fourth quarter.
-
Global Blood has sights on FDA accelerated approval with sickle cell drug data
The company presented updated data for the drug, voxelotor, at the European Hematology Association conference in Amsterdam Friday.